Medifast Forecasts Q2 Loss of $0.50-$1.00/Share Amid Continued Struggles
MED sits 19% above its 52-week low of $9.22.
Summary
Medifast has issued guidance for the second quarter, projecting a loss per share in the range of $0.50 to $1.00. This specific negative outlook for Q2 follows the company's recent Q1 earnings report, which revealed a substantial 34% year-over-year revenue decline and a net loss, reinforcing the ongoing financial challenges highlighted in its 2025 annual report. The quantified Q2 loss projection provides new, concrete data points for traders, confirming the negative trajectory and likely adding further pressure on the stock. Investors will closely monitor actual Q2 results and any strategic initiatives the company may announce to address declining sales and profitability in a competitive market.
At the time of this announcement, MED was trading at $11.00 on NYSE in the Trade & Services sector, with a market capitalization of approximately $117.3M. The 52-week trading range was $9.22 to $15.46. This news item was assessed with negative market sentiment and an importance score of 8 out of 10. Source: Dow Jones Newswires.